Sodium-glucose cotransporter-2 inhibitors: where and when?

Published in: Future cardiology (2021)

Tweetable abstract Sodium-glucose cotransporter-2 inhibitors not only improve glycemic control in Type 2 diabetes mellitus but convincingly improve outcome for everyone with HFrEF and albuminuric kidney disease. Trials then license - now all we need is implementation.

Keyphrases

glycemic control
type diabetes
blood glucose
primary care
healthcare
weight loss
quality improvement
adipose tissue